Isabella Ciccone

2 weeks ago | neurologylive.com | Sam I. Hooshmand |Isabella Ciccone

The Whitaker Track Invited Lectures session, MS in Special Populations, presented at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 28-31, 2025, in Phoenix, Arizona, offered a comprehensive look at the unique challenges and considerations in managing multiple sclerosis (MS) across diverse patient groups.

3 weeks ago | neurologylive.com | Ahmed Abdelhak |Isabella Ciccone

Emerging serum and imaging biomarkers are currently aiming to enhance the ability to monitor remyelination in multiple sclerosis (MS). For example, serum neurofilament light chain (NfL) has emerged as a promising biomarker, reflecting neuroaxonal damage and correlating with disease activity and progression. Recent research has shown that elevated serum NfL levels were associated with an increased risk of disability and brain atrophy.

3 weeks ago | neurologylive.com | Sumaira Ahmed |Isabella Ciccone

WATCH TIME: 2 minutes"We are super hopeful and excited about all that we will learn, especially what it will mean for patients, about the different therapies available to [those with NMOSD] and which ones may be best suited for them."Despite the influx of recently approved therapies for patients with neuromyelitis optica spectrum disorder (NMOSD), patients still opt to use off-label treatments like rituximab to suppress disease activity.

3 weeks ago | neurologylive.com | Ahmed Abdelhak |Isabella Ciccone

WATCH TIME: 5 minutes "I think we demonstrated in a robust way that if you cause demyelination, neurofilament light (NfL) will go up, and if you remyelinate the axons, NfL levels will be lower." At the recently concluded 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 28-31, 2025, in Phoenix, the session titled “Promoting Remyelination in MS” provided attendees with a comprehensive overview of current scientific, clinical, and translational efforts aimed at...

3 weeks ago | neurologylive.com | Isabella Ciccone

A systematic review and meta-analysis presented as a late breaker at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 28-31, 2025, in Phoenix, Arizona, revealed that cognitive behavioral therapy (CBT) did not effectively improve fatigue severity or fatigue impact in individuals with multiple sclerosis (MS).1Investigators performed a comprehensive literature search and included 24 studies in their systematic review.